NASDAQ: MSLESatellos Bioscience Inc Stock
$11.25
Updated Feb 6, 2026
MSLE Price
$11.25
Fair Value Price
N/A
Market Cap
$165.29M
52 Week Low
$11.00
52 Week High
$12.14
P/E
N/A
P/B
4.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MSLE Overview
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MSLE's potential to beat the market
- MSLE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MSLE
RankedUnranked of 483
RankedUnranked of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.38 | A | |
| $165.50 | A | |
| $16.09 | A |
Be the first to know about important MSLE news, forecast changes, insider trades & much more!
MSLE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MSLE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MSLE is good value based on its book value relative to its share price (4.31x), compared to the US Biotechnology industry average (5.16x)
P/B vs Industry Valuation
MSLE's short-term assets ($41.11M) exceed its short-term liabilities ($2.77M)
Short-term Liabilities Financials
MSLE's short-term assets ($41.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more MSLE due diligence checks available for Premium users.
Valuation
MSLE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.31x
Industry
5.16x
MSLE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MSLE's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.6M
Profit Margin
0%
Assets to liabilities
Assets
$41.1M
Liabilities
$2.8M
Debt to equity
0.07
MSLE's short-term assets ($41.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MSLE's short-term assets ($41.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MSLE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MSLE vs Biotech Stocks
Satellos Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.